Stults C L, Macher B A
Department of Chemistry and Biochemistry, San Francisco State University, California 94132.
Arch Biochem Biophys. 1993 May 15;303(1):125-33. doi: 10.1006/abbi.1993.1263.
There are well-established differences in the expression of neolacto neutral glycosphingolipids among human leukocyte subclasses. Mature myeloid cells express several types of these compounds, whereas mature lymphoid cells are deficient in such compounds. The biochemical basis for this is unknown. Therefore, enzyme studies were done to determine whether different classes of leukocytes (represented by cell lines) contained beta 1-3-N-acetylglucosaminyltransferase activity (EC 2.4.1.149, beta 1-3GlcNAcT(i)). This enzyme participates in the synthesis of Type 2 chains in glycosphingolipids by catalyzing the following two reactions: (i) Gal beta 1-4Glc beta 1-1Cer (lactosylceramide, LacCer) + UDP-GlcNAc-->GlcNAc beta 1-3Gal beta 1-4Glc beta 1- 1Cer (lactotriaosylceramide) and (ii) Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc beta 1-1Cer (neolactotetraosylceramide) + UDP-GlcNAc-->GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc beta 1-1Cer. The first reaction may be the key step in the biosynthetic pathway of neolacto structures in human leukocytes. Therefore, extracts from several cell lines representative of both myeloid and lymphoid lineages, at varied stages of maturity, were assayed with LacCer for the presence of beta 1-3GlcNAcT(i) activity. Our results indicate that myeloid cells contain this initiating beta 1-3GlcNAcT(i) activity, whereas lymphoid cells do not. This is consistent with our thin-layer chromatography immunostain results which show that all myeloid cell lines express neutral neolacto glycosphingolipids and lymphoid cells do not. Our findings suggest that the presence of the initiating activity only in myeloid cells is a regulatory factor in the expression of neutral neolacto glycosphingolipids in human leukocytes. We also tested both myeloid and lymphoid cell lines for the presence of elongating beta 1-3GlcNAcT(i) activity (reaction (ii) above) by using neolactotetraosylceramide as an acceptor. Our results show that an elongating activity is expressed by all myeloid and lymphoid cell lines tested. Initiating (myeloid) and elongating (myeloid and lymphoid) activities were distinguished by several characteristics: metal ion activation, pH optimum, and kinetic constants. In conclusion, our results indicate the presence of two beta 1-3GlcNAcT(i) activities in human leukocytes: one that catalyzes the initial reaction and is found only in the myeloid lineage and one that catalyzes the elongating reaction and is found in both myeloid and lymphoid cells.
人类白细胞亚类中新乳糖中性糖鞘脂的表达存在公认的差异。成熟髓细胞表达几种这类化合物,而成熟淋巴细胞缺乏这类化合物。其生化基础尚不清楚。因此,进行了酶学研究以确定不同类别的白细胞(以细胞系为代表)是否含有β1-3-N-乙酰葡糖胺基转移酶活性(EC 2.4.1.149,β1-3GlcNAcT(i))。该酶通过催化以下两个反应参与糖鞘脂中2型链的合成:(i)Galβ1-4Glcβ1-1Cer(乳糖基神经酰胺,LacCer)+UDP-GlcNAc→GlcNAcβ1-3Galβ1-4Glcβ1-1Cer(乳糖三糖基神经酰胺)和(ii)Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1Cer(新乳糖四糖基神经酰胺)+UDP-GlcNAc→GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1Cer。第一个反应可能是人类白细胞中新乳糖结构生物合成途径中的关键步骤。因此,用LacCer检测了来自代表髓系和淋巴系的几种处于不同成熟阶段的细胞系提取物中β1-3GlcNAcT(i)活性的存在情况。我们的结果表明,髓细胞含有这种起始β1-3GlcNAcT(i)活性,而淋巴细胞则没有。这与我们的薄层色谱免疫染色结果一致,该结果表明所有髓细胞系都表达中性新乳糖糖鞘脂,而淋巴细胞则不表达。我们的发现表明,仅在髓细胞中存在起始活性是人类白细胞中中性新乳糖糖鞘脂表达的一个调节因子。我们还通过使用新乳糖四糖基神经酰胺作为受体,检测了髓系和淋巴系细胞系中延伸β1-3GlcNAcT(i)活性(上述反应(ii))的存在情况。我们的结果表明,所有测试的髓系和淋巴系细胞系都表达延伸活性。起始(髓系)和延伸(髓系和淋巴系)活性通过几个特征来区分:金属离子激活、最适pH值和动力学常数。总之,我们的结果表明人类白细胞中存在两种β1-3GlcNAcT(i)活性:一种催化初始反应,仅存在于髓系谱系中;另一种催化延伸反应,存在于髓系和淋巴细胞中。